Abivax announces advances in its clinical program and updates its operations

Abivax provided an update on the status of its flagship clinical program, ABTECT. The phase 3 trial is evaluating Obefazimod for moderate to severe ulcerative colitis (UC). Patient recruitment is expected to be completed in early 2025, with initial results expected in the second quarter of 2025. Maintenance data is expected in the first quarter of 2026.

The company also announced progress in its preclinical program and appointments to key positions: Sylvie Grégoire as Chairman of the Board of Directors, Fabio Cataldi as Chief Medical Officer, and David Zhang as Chief Strategy Officer.

Abivax's cash position will be able to support its activities until the fourth quarter of 2025, thus ensuring the continuity of its clinical projects.